ReForm Biologics Appoints John M. Sorvillo, Ph.D., as Chief Executive Officer

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

April 19, 2017

ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced today that the Company’s Board of Directors has appointed John M. Sorvillo, Ph.D., as Chief Executive Officer.

Reform Biologics notes John M. Sorvillo Ph.D. brings over 25 years of experience leading the development and licensing of technologies, from discovery platforms and research programs to pre-clinical and clinical products, across a range of therapeutic areas.

“Dr. Sorvillo offers a wealth of business development, strategic planning, alliance building and project management experience that complements the scientific expertise of ReForm’s founding team,” said David Soane, Ph.D., Co-founder and Chief Technology Officer of ReForm Biologics. “John’s extensive knowledge of drug discovery and development technologies will further expand the industry applications for our platform by creating value-driven development collaborations with our current and future partners.”

Dr. Sorvillo joins ReForm Biologics from Amgen, where he was Director of Business Development & Licensing. Prior to Amgen, he served as Vice President of Business Development at Genocea Biosciences, and Vice President of Business Development at Altus Pharmaceuticals.

Before joining Altus, Dr. Sorvillo served as Chief Executive Officer of Bionaut Pharmaceuticals. His earlier responsibilities included Vice President of Business Development at ArQule, and a variety of positions at OSI Pharmaceuticals, including Vice President and General Manager of the Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, and received his Ph.D. in Immunology from the New York University Medical Center, Sackler Institute of Biomedical Sciences. He holds a B.A. in Biology from the City University of New York, Hunter College.

“ReForm’s breakthrough technologies, driven by our amazing scientific team, are poised to transform the next generation of biologic medicines,” said Dr. Sorvillo. “I have the privilege of building on ReForm’s success to date and look forward to advancing patient care by making biologics better.”



Related Articles